Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis

Wang,Shiqun; Li,Lu; Shi,Long

doi:10.3892/mmr.2019.10494

Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis

Authors:
- Shiqun Wang
- Lu Li
- Long Shi
View Affiliations

Affiliations: Xiaoshan Biotechnology Center, Yangtze Delta Region Institute of Tsinghua University, Hangzhou, Zhejiang 311231, P.R. China, Department of Nephrology, Affiliated Children's Hospital of Zhejiang University, Hangzhou, Zhejiang 310052, P.R. China
Published online on: July 12, 2019 https://doi.org/10.3892/mmr.2019.10494
Pages: 2657-2666
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glycyrrhizic acid (GA) is primarily used as an anti‑inflammatory agent in cases of chronic hepatitis. However, its underlying mechanisms in diverse biological processes and its reported benefits are yet to be fully elucidated. In the current study, an analytical method based on pharmacogenomics was established to mine disease‑modulatory activities mediated by GA. Five primary protein targets and 138 functional partners were identified for GA by querying open‑source databases, including Drugbank and STRING. Subsequently, GA‑associated primary and secondary protein targets were integrated into Cytoscape to construct a protein‑protein interaction network to establish connectivity. GA‑associated target genes were then clustered based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The tumor necrosis factor axis was revealed to be a primary module regulated by GA‑associated targets. Furthermore, 12 hub genes were queried to assess their potential anti‑cancer effects using cBioPortal. The results indicated that pharmacogenomics‑based analysis improved understanding of the underlying drug‑target events of GA and provided predictive and definitive leads for future studies.

View Figures

View References

1	Saif MW, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, Bussom S, Liu SH and Cheng YC: First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 73:373–380. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ming LJ and Yin AC: Therapeutic effects of glycyrrhizic acid. Nat Prod Commun. 8:415–418. 2013.PubMed/NCBI
3	Farrukh MR, Nissar UA, Kaiser PJ, Afnan Q, Sharma PR, Bhushan S and Tasduq SA: Glycyrrhizic acid (GA) inhibits reactive oxygen Species mediated photodamage by blocking ER stress and MAPK pathway in UV-B irradiated human skin fibroblasts. J Photochem Photobiol B. 148:351–357. 2015. View Article : Google Scholar : PubMed/NCBI
4	Fouladi S, Masjedi M, Ghasemi R, G Hakemi M and Eskandari N: The in vitro impact of glycyrrhizic acid on CD4⁺ T lymphocytes through OX40 receptor in the patients with allergic rhinitis. Inflammation. 41:1690–1701. 2018. View Article : Google Scholar : PubMed/NCBI
5	He SQ, Gao M, Fu YF and Zhang YN: Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling. Int J Clin Exp Pathol. 8:5175–5181. 2015.PubMed/NCBI
6	Hou S, Zhang T, Li Y, Guo F and Jin X: Glycyrrhizic acid prevents diabetic nephropathy by activating AMPK/SIRT1/PGC-1α signaling in db/db mice. J Diabetes Res. 2017:28659122017. View Article : Google Scholar : PubMed/NCBI
7	Kiratipaiboon C, Tengamnuay P and Chanvorachote P: Glycyrrhizic acid attenuates stem cell-like phenotypes of human dermal papilla cells. Phytomedicine. 22:1269–1278. 2015. View Article : Google Scholar : PubMed/NCBI
8	Li C, Peng S, Liu X, Han C, Wang X, Jin T, Liu S, Wang W, Xie X, He X, et al: Glycyrrhizin, a direct HMGB1 antagonist, ameliorates inflammatory infiltration in a model of autoimmune thyroiditis via inhibition of TLR2-HMGB1 signaling. Thyroid. 27:722–731. 2017. View Article : Google Scholar : PubMed/NCBI
9	Lin SC, Chu PY, Liao WT, Wu MY, Tsui KH, Lin LT, Huang CH, Chen LL and Li CJ: Glycyrrhizic acid induces human MDA-MB-231 breast cancer cell death and autophagy via the ROS-mitochondrial pathway. Oncol Rep. 39:703–710. 2018.PubMed/NCBI
10	Refahi S, Pourissa M, Zirak MR and Hadadi G: Modulation expression of tumor necrosis factor α in the radiation-induced lung injury by glycyrrhizic acid. J Med Phys. 40:95–101. 2015. View Article : Google Scholar : PubMed/NCBI
11	Wang LY, Cheng KC, Li Y, Niu CS, Cheng JT and Niu HS: Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 95:599–604. 2017. View Article : Google Scholar : PubMed/NCBI
12	Wang YM and Du GQ: Glycyrrhizic acid prevents enteritis through reduction of NF-κB p65 and p38MAPK expression in rat. Mol Med Rep. 13:3639–3646. 2016. View Article : Google Scholar : PubMed/NCBI
13	Yang J, Shi Y, Chen H, Wang X, Chen Y and Yang B: Glycyrrhizic acid attenuates myocardial injury: Involvement of RIP140/NF-κB Pathway. Biomed Pharmacother. 95:62–67. 2017. View Article : Google Scholar : PubMed/NCBI
14	Zhang H, Zhang R, Chen J, Shi M, Li W and Zhang X: High mobility group Box1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats. Kidney Blood Press Res. 42:894–904. 2017. View Article : Google Scholar : PubMed/NCBI
15	Relling MV and Evans WE: Pharmacogenomics in the clinic. Nature. 526:343–350. 2015. View Article : Google Scholar : PubMed/NCBI
16	Mooney SD: Progress towards the integration of pharmacogenomics in practice. Hum Genet. 134:459–465. 2015. View Article : Google Scholar : PubMed/NCBI
17	Campedel L, Kossaï M, Blanc-Durand P, Rouprêt M, Seisen T, Compérat E, Spano JP and Malouf G: Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions. Bull Cancer. 104:789–799. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
18	Su G, Morris JH, Demchak B and Bader GD: Biological network exploration with Cytoscape 3. Curr Protoc Bioinformatics. 47:8.13.1–24. 2014. View Article : Google Scholar
19	Guo Y, Bao Y, Ma M and Yang W: Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int J Mol Sci. 18(pii): E7222017. View Article : Google Scholar : PubMed/NCBI
20	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
21	Canault B, Bourg S, Vayer P and Bonnet P: Comprehensive network map of ADME-Tox databases. Mol Inform. 36:2017. View Article : Google Scholar : PubMed/NCBI
22	Coelho-Santos V, Leitão RA, Cardoso FL, Palmela I, Rito M, Barbosa M, Brito MA, Fontes-Ribeiro CA and Silva AP: The TNF-α/NF-κB signaling pathway has a key role in methamphetamine-induced blood-brain barrier dysfunction. J Cereb Blood Flow Metab. 35:1260–1271. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kang R, Xie Y, Zhang Q, Hou W, Jiang Q, Zhu S, Liu J, Zeng D, Wang H, Bartlett DL, et al: Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res. 27:916–932. 2017. View Article : Google Scholar : PubMed/NCBI
24	Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, et al: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
25	Asl MN and Hosseinzadeh H: Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 22:709–724. 2008. View Article : Google Scholar : PubMed/NCBI
26	Brumatti G, Salmanidis M and Ekert PG: Crossing paths: Interactions between the cell death machinery and growth factor survival signals. Cell Mol Life Sci. 67:1619–1630. 2010. View Article : Google Scholar : PubMed/NCBI
27	Hayden MS and Ghosh S: Regulation of NF-κB by TNF family cytokines. Semin Immunol. 26:253–266. 2014. View Article : Google Scholar : PubMed/NCBI
28	Yaw HP, Ton SH, Chin HF, Karim MK, Fernando HA and Kadir KA: Modulation of lipid metabolism in glycyrrhizic acid-treated rats fed on a high-calorie diet and exposed to short or long-term stress. Int J Physiol Pathophysiol Pharmacol. 7:61–75. 2015.PubMed/NCBI
29	Chen S, Jiang S, Zheng W, Tu B, Liu S, Ruan H and Fan C: RelA/p65 inhibition prevents tendon adhesion by modulating inflammation, cell proliferation, and apoptosis. Cell Death Dis. 8:e27102017. View Article : Google Scholar : PubMed/NCBI
30	Miot C, Imai K, Imai C, Mancini AJ, Kucuk ZY, Kawai T, Nishikomori R, Ito E, Pellier I, Dupuis Girod S, et al: Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations. Blood. 130:1456–1467. 2017. View Article : Google Scholar : PubMed/NCBI
31	Wei B, Liang J, Hu J, Mi Y, Ruan J, Zhang J, Wang Z, Hu Q, Jiang H and Ding Q: TRAF2 is a valuable prognostic biomarker in patients with prostate cancer. Med Sci Monit. 23:4192–4204. 2017. View Article : Google Scholar : PubMed/NCBI
32	Wei B, Ruan J, Mi Y, Hu J, Zhang J, Wang Z, Hu Q, Jiang H and Ding Q: Knockdown of TNF receptor-associated factor 2 (TRAF2) modulates in vitro growth of TRAIL-treated prostate cancer cells. Biomed Pharmacother. 93:462–469. 2017. View Article : Google Scholar : PubMed/NCBI
33	Jin H, Dong YY, Zhang H, Cui Y, Xie K and Lou G: shRNA depletion of cIAP1 sensitizes human ovarian cancer cells to anticancer agent-induced apoptosis. Oncol Res. 22:167–176. 2014. View Article : Google Scholar : PubMed/NCBI
34	Seidelin JB: Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis. Scand J Gastroenterol. 50 (Suppl 1):S1–S29. 2015. View Article : Google Scholar
35	Hostetler BJ, Uchakina ON, Ban H and McKallip RJ: Treatment of hematological malignancies with glycyrrhizic acid. Anticancer Res. 37:997–1004. 2017. View Article : Google Scholar : PubMed/NCBI
36	Kim KJ, Choi JS, Kim KW and Jeong JW: The anti-angiogenic activities of glycyrrhizic acid in tumor progression. Phytother Res. 27:841–846. 2013. View Article : Google Scholar : PubMed/NCBI
37	Doss GP, Agoramoorthy G and Chakraborty C: TNF/TNFR: Drug target for autoimmune diseases and immune-mediated inflammatory diseases. Front Biosci (Landmark Ed). 19:1028–1040. 2014. View Article : Google Scholar : PubMed/NCBI
38	Berman-Booty LD and Knudsen KE: Models of neuroendocrine prostate cancer. Endocr Relat Cancer. 22:R33–R49. 2015. View Article : Google Scholar : PubMed/NCBI
39	Guo R, Tu Y, Xie S, Liu XS, Song Y, Wang S, Chen X and Lu L: A role for receptor-interacting protein kinase-1 in neutrophil extracellular trap formation in patients with systemic lupus erythematosus: A preliminary study. Cell Physiol Biochem. 45:2317–2328. 2018. View Article : Google Scholar : PubMed/NCBI
40	Ando K, Sakoda M, Ueno S, Hiwatashi K, Iino S, Minami K, Kawasaki Y, Hashiguchi M, Tanoue K, Mataki Y, et al: Clinical implication of the relationship between high mobility group Box-1 and tumor differentiation in hepatocellular carcinoma. Anticancer Res. 38:3411–3418. 2018. View Article : Google Scholar : PubMed/NCBI
41	Zhang Y, Li L, Qi C, Hua S, Fei X, Gong F and Fang M: Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25. Biomed Pharmacother. 110:692–699. 2019. View Article : Google Scholar : PubMed/NCBI
42	Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F and Drulovic J: The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol. 207:101–106. 2009. View Article : Google Scholar : PubMed/NCBI
43	Shin MS, Kang Y, Wahl ER, Park HJ, Lazova R, Leng L, Mamula M, Krishnaswamy S, Bucala R and Kang I: Macrophage migration inhibitory factor regulates U1 small nuclear RNP immune complex-mediated activation of the NLRP3 inflammasome. Arthritis Rheumatol. 71:109–120. 2019. View Article : Google Scholar : PubMed/NCBI
44	Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, Ingelman-Sundberg M and Papaluca-Amati M: Pharmacogenomic information in drug labels: European medicines agency perspective. Pharmacogenomics J. 15:201–210. 2015. View Article : Google Scholar : PubMed/NCBI